Tumour volume reduction during CRT linked to worse survival in locally advanced lung adenocarcinoma
Reduction in gross tumour volume (GTV) during concurrent chemoradiation therapy (CRT) may be linked to worse overall survival (OS) in patients with locally advanced lung adenocarcinoma, according to a recent study reported at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).
In the study, 394 patients treated with concurrent CRT for locally advanced non-small-cell lung cancer (NSCLC) had their GTV measured on cone beam CT scan between the first and last fraction of radiotherapy. [Kwint M, et al, WCLC 2018, abstract P1.17-07]
“It is important to determine tumour response during treatment and its relationship with clinical outcomes. However, previously published literature in NSCLC patients has been inconsistent about this association,” wrote researchers from the Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Results showed that in NSCLC patients who had adenocarcinoma histology, >median GTV change during concurrent CRT was associated with worse OS (p=0.060).
Surprisingly, no such associations were found for the entire cohort, or in those with squamous (p=0.770) or unspecified histology (p=0.952). “In the entire cohort, we could not identify any associations between GTV changes during concurrent CRT and OS, progression-free survival or locoregional control,” the researchers added.